Please assess the completion status of the following clinical trial:

Trial Title: Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Patients must have histologically confirmed hairy cell leukemia or hairy cell leukemia variant .with a need for therapy~* Patients must be Pseudomonas-immunotoxin naive~* Patients must have had at least 2 prior purine analogs, or at least 1 course of purine analog and 1 of either rituximab or BRAF inhibitor.~* Men or women age greater than or equal to 18 years.~* ECOG performance status less than or equal to 2.~* Patients must have adequate organ function~EXCLUSION CRITERIA~* Patients who have had chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to entering the study.~* Patients who are receiving any other investigational agents.~* Patients with known brain metastases should be excluded from this clinical trial~* Patients with clinically significant ophthalmologic findings during screening~* Pregnant or breastfeeding females.~* Positive for Hepatitis B core antibody or surface antigen unless the patient is on Lamivudine or Entecavir and Hepatitis B Viral DNA load is less than 2000 IU/mL.~* Active second malignancy requiring treatment other than minor resection of indolent cancers like basal cell and squamous skin cancers~* HIV-positive patients unless taking appropriate anti-HIV medications with a CD4 count of greater than 200.~* History of allogeneic bone marrow transplant.~* Patients with history of both thromboembolism and known congenital hypercoagulable conditions.~* Uncontrolled pulmonary infection, pulmonary edema.~* Adequate oxygen saturation~* Radioimmunotherapy within 2 years prior to enrollment in study.~* Adequate hematologic function~* Adequate lung function~* Patients with history of thrombotic microangiopathy or thrombotic microangiopathy / hemolytic uremic syndrome~* Patients with QTc interval (Friderica) elevation \> 500 msec based on at least 2 separate 12-lead ECGs~* Patient on high dose estrogen~* Patients with clinical evidence of disseminated intravascular coagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Moxetumomab pasudotox 40 µg/kg (Type: EXPERIMENTAL): Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.

Based on this trial design, predict the completion outcome and termination type (if applicable).